Corvus Pharmaceuticals, Inc. Banner Image

Corvus Pharmaceuticals, Inc. has reached its limit for free report views

Work for Corvus Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Corvus Pharmaceuticals, Inc.

  • Ticker CRVS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Corvus Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Burlingame, California
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and activation of immune cells. These product candidates are being studied in ongoing Phase 1b/2 and PhaseMore 1/1b clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort Phase 1b/2 trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s third cancer clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. The Company is also evaluating CPI-006 as a treatment for COVID-19 patients.
Corvus Pharmaceuticals, Inc.

Most Recent Annual Report

Corvus Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Corvus Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports